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Abstract
So-called ‘neglected tropical diseases’ (NTDs) are becoming less neglected, with increasing
political and financial commitments to their control. These recent developments were preceded by
substantial advocacy for integrated control of different NTDs, on the premise that integration is
both feasible and cost-effective. Although the approach is intuitively attractive, there are few
countrywide experiences to confirm or refute this assertion. Using the example of Uganda, this
article reviews the geographical and epidemiological bases for integration and assesses the
potential opportunities for, and operational challenges of, integrating existing control activities for
several of these diseases under an umbrella vertical programme.
Potential for integration
Greater emphasis is being given to controlling neglected tropical diseases [NTDs; Neglected
tropical diseases, hidden successes, emerging opportunities
(http://whqlibdoc.who.int/hq/2006/WHO_CDS_NTD_2006.2_eng.pdf)]. The term ‘NTDs’
is used because they exclusively affect the poor and marginalized in low-income countries
and, until recently, received little or no advocacy or funding. The most important African
NTDs are shown in Table 1. Although these diseases are thought to kill up to 500 000
people per year [1], mortality figures alone do not capture the main impact of NTDs on
public health, which largely arises from chronic disability and morbidity [2]. In an effort to
control or eliminate this disease burden, several global vertical initiatives have been
established [3]. Since 2004, there has been greater advocacy for the logistical and economic
benefits of integrated control of NTDs, whereby different treatment strategies are bundled
together [4–6]. Integration can also involve another aspect: linking intervention packages
with ongoing healthcare delivery [7].
Small-scale efforts to integrate vertical NTD programmes have been undertaken in several
African countries. For example, in Nigeria, integrated distribution of anthelmintic treatments
combined with insecticide-treated nets (ITNs) by community-based volunteers resulted in
increased uptake of ITNs without an adverse effect on the coverage of mass drug
administration (MDA) [8]. To help support national programmes, the World Health
Organization (WHO) has recently published guidelines on integrated helminthiasis control,
which have been designed to deal with drugs and their coordinated use in all
epidemiological situations, including those in which there is limited geographical overlap
[Preventive chemotherapy in human helminthiasis
(http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf)]. In addition, the Global
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Network for Neglected Tropical Disease Control was launched in October 2006, with the
aim of providing advocacy and coordinating the efforts of NTD-control partners [9].
However, although the concept of integration is logistically and economically appealing,
experience at the country level is surprisingly limited.
Similar to many other developing countries, Uganda is affected by a high burden of NTDs:
visceral leishmaniasis (VL; kala-azar) [10], human African trypanosomiasis (HAT) [11],
trachoma [12], Buruli ulcer [13], soil-transmitted helminths (STHs) [14], schistosomiasis
owing to Schistosoma mansoni [15], lymphatic filariasis (LF) [16] and onchocerciasis [17]
(Table 2). Dracunculiasis and leprosy have recently been eliminated from the country [18].
Uganda provides a useful insight into the control of NTDs because it is one of the few
African countries that has undertaken nationwide assessments for several NTDs [15–17] and
already piloted integrated control [19]. It also implements a broader integrated health
package through the Child Health Days (CHDs) instigated by the Ministry of Health (MoH)
and is one of five African ‘fast-track’ countries that receives support from the US Agency
for International Development (USAID), to develop an integrated NTD control programme
[RTI launches integrated program to address neglected tropical diseases
(http://www.rti.org/newsroom)]. Implementation of such a package necessitates careful
consideration of several issues, including the geography, epidemiology and ecology of
different NTDs, in addition to the advantages and disadvantages of existing control
strategies.
Geography of integrated control
Understanding which geographical areas require intervention is fundamental for cost-
effective disease control. NTDs in Uganda have been mapped using a variety of survey
methodologies. The distribution of onchoceriasis has been estimated using the rapid
epidemiological mapping of onchoceriasis (REMO) method [20], enabling communities to
be classified into three categories: priority areas requiring community-directed drug
treatment with ivermectin (CDTI); areas not requiring treatment; and possible endemic areas
requiring further investigation [17]. Rapid mapping of LF included school surveys using
immunochromatographic antigenic detection cards and the application of geostatistical
methods to create a nationwide estimation of the prevalence of LF [16]. The distributions of
schistosomiasis and STH infections were defined according to nationwide parasitological
surveys [14,15]. More recently, rapid mapping of schistosomiasis used lot quality-assurance
sampling (LQAS) to finely target control [21]. LQAS has also been used to estimate the
prevalence of Trypanosoma brucei gambiense trypanosomiasis in northern Uganda,
enabling communities to be ranked according to prevalence categories [22]. Elsewhere,
distributions of HAT have been assessed using expensive case detection by passive or
population mass screening: T. b. gambiense occurs in northwestern Uganda, whereas
Trypanosoma brucei rhodesiense has traditionally occurred in southeastern areas [23]. These
two foci are currently geographically separated but are becoming worryingly close [11,24].
The endemicity of VL has, so far, been defined only on the basis of passive case-detection
data, which suggest that the disease is restricted to Pokot county, a semiarid lowland area in
the Nakapiripirit district [10]; however, there are concerns that VL might be endemic over a
larger area. Trachoma is thought to be endemic in at least 26 districts, putting ∼7 million
people at risk. A nationwide survey is planned, to provide detailed data on the distribution
and burden of trachoma.
On the basis of these geographical assessments, it is possible to qualitatively define the
codistribution of different NTDs (Figure 1). Existing data indicate that onchocerciasis,
schistosomiasis and LF are coendemic in ten districts of northwestern Uganda, putting
>500 000 people at risk of coacquiring them. LF is coendemic with schistosomiasis in at
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least 19 districts and with onchocerciasis in at least 13 districts. Further surveys are required
to confirm whether coendemicity applies to whole districts or is more localized.
Epidemiology and ecology of integrated control
Control of different NTDs must be based on a detailed understanding of their
epidemiologies and modes of parasite transmission. The target age-groups might differ
between NTDs [4]. The prevalence and intensity of schistosomiasis and STHs (except
hookworm) are greatest among school-age children or young adults and decrease throughout
adulthood [15,25], whereas for LF and hookworm age-specific prevalence rises throughout
childhood and attains a stable asymptote, or rises marginally, in adulthood [26–28].
Epidemiological patterns of onchocerciasis vary markedly between geographical zones [29];
in Uganda, the prevalence of infection increases throughout childhood and reaches a plateau
at 20 years, whereas the occurrence of nodules and onchocercal dermatitis increases
throughout childhood and adulthood [30,31]. Thus, school-age children are the natural
targets for population-based treatment of STHs and schistosomiasis, whereas
communitywide treatment is warranted for LF and onchocerciasis.
LF and onchocerciasis are vector-borne diseases, transmitted by several genera of
mosquitoes and blackflies of the Simulium genus, respectively. Vector control has been
highly effective in the control of onchocerciasis [32], for which the stated goal is
interruption of transmission, and might potentially have a significant role in elimination of
LF [33]. In both cases, communities within whole districts should be targeted with
interventions [34,35]. Transmission of STHs and schistosomiasis depends on contamination
of soil and snail-infested water with human faeces and urine, hindering elimination in
settings with inadequate water supply and sanitation. Consequently, the goal of
schistosomiasis and STH control is the reduction of morbidity, hence interventions typically
target age-groups with the greatest morbidity, namely school-age children and young adults
in high-prevalence communities or subdistricts [36,37]. These different treatment goals and
intervention units require consideration in the design of integrated treatment programmes for
NTDs.
HAT is transmitted by tsetse flies and occurs more often in adults [38], whereas VL is
transmitted by sandflies and, at least in Uganda, is most common in children and teenagers
[10]. Vector control can make an important contribution to reducing the burden of both
diseases [39–41], but it is rarely implemented because of a lack of financial resources.
Treatment is lengthy, expensive and relatively toxic. Development of new drugs and
adequate diagnostic tools has been slow [42,43], although a reliable rapid diagnostic test for
VL is now available [44].
Current control of neglected tropical diseases in Uganda
The control of most NTDs is the mandate of the Vector Control Division (VCD) of the
Ugandan MoH. The VCD was established in the early 1920s and led national vector-borne
disease control until the 1970s, when it virtually collapsed during military rule, only being
rehabilitated in 1994 [45].
The longest-running control programme in the VCD is the national onchocerciasis control
programme, established in 1992. Since the mid-1990s, it has been supported by the Carter
Centre's Global 2000 River Blindness Programme, Sight Savers International, the
Gesellschaft für Technische Zusammenarbeit and the African Programme for
Onchocerciasis Control. Intervention consists of annual CDTI, supplemented by vector
control in isolated foci of Simulium neavei [46,47]. To date, geographical treatment
coverage has reached 100% and therapeutic coverage remains stable at 80%. Large-scale
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vector control is unfeasible because the breeding sites are too widespread or inaccessible and
extend into politically unstable countries, such as the Democratic Republic of Congo.
The cornerstone of LF control is annual MDA of a single dose of ivermectin and
albendazole, provided to the entire ‘at-risk’ population in targeted districts. The first MDA
for LF was carried out at the end of 2002 in two districts with a total population of 1 million
people, reaching ∼75% coverage. Scaling up the programme to cover eight adjacent
districts, planned for 2003, was delayed because of insecurity and insufficient operational
funds. In 2004, MDA was carried out in five districts, with a total population of >2 million,
and, in 2005, the programme was extended to cover ten districts, with a total population of
4.9 million. In 2006 no distribution took place, owing to a lack of funds for drug delivery.
MDA is carried out in schools and communities by trained teachers and community drug
distributors (CDDs), respectively, with most districts having reached at least 65% coverage.
It is increasingly appreciated that the use of ivermectin and albendazole in MDA for the
elimination of LF has ancillary benefits against onchocerciasis and STHs [4].
For the combined control of schistosomiasis and STH infections, a national programme was
established in 2003 [48], with support from the Schistosomiasis Control Initiative. The
programme is managed centrally by the VCD, but it is implemented by district health teams.
MDA of praziquantel and albendazole is provided to all school children in target
subcounties (at the subdistrict level) and the whole community in areas where prevalence of
infection exceeds 50%. Treatment is carried out by teachers and CDDs in schools and
communities, respectively [49].
HAT control activities, consisting of the mass treatment of livestock using trypanocides and
vector control, were implemented in parts of the Soroti district between January 2000 and
December 2003. However, a survey conducted in 2004 of Soroti markets showed a high
prevalence of T. b. rhodesiense in cattle bought from areas in southeast Uganda with
endemic sleeping sickness. This showed that control activities have been largely ineffective,
and the trade and resultant movement of animals infected with trypanosomes continues [11].
Currently, no control is undertaken against VL, Buruli ulcer or trachoma.
Progress and prospects of integrated control
The feasibility study of integrating treatment for onchocerciasis with schistosomiasis and
STH infections showed that the treatment coverage of ivermectin, praziquantel and
mebendazole were increased using the integrated approach [19]. An identified disadvantage
was that supplies of praziquantel and mebendazole ran out more frequently, because
treatments were being administered to nontarget groups. The investigators suggested that the
CDDs might have thought that they or their immediate relatives had schistosomiasis and/or
STH infections, and thus treated themselves or their family before treating the targeted high-
risk groups in the neighbourhood. Despite the promising results, integration has not been put
into practice to date, although financial support from the USAID aims to expand integrated
delivery of anthelmintic treatment from 2007.
STH control also forms one of the components of the CHDs in Uganda, which take place
twice each year (in April and October). CHDs are a period of accelerated routine maternal
and child health interventions, delivered at all static health units and through outreach in
communities and schools. The package of interventions includes vitamin A
supplementation, childhood vaccination and promotion of hygiene at home and school.
Implementation is through a multidisciplinary team of health workers, community members
(including CDDs), vaccinators and mobilizers. The provision of annual albendazole
treatment by this integrated approach improves the nutritional status of young children [50].
Kolaczinski et al. Page 4
Published as: Trends Parasitol. 2007 October ; 23(10-3): 485–493.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
The strategy proposed for integrated control of LF, onchocerciasis, schistosomiasis, STHs
and trachoma, to be supported by the USAID, focuses on the integration of individual drug-
delivery activities under an umbrella programme, to provide simultaneous, or almost
simultaneous, population-based treatment. Only four drugs – albendazole, ivermectin,
praziquantel and azithromycin – are used to control seven major NTDs – schistosomiasis,
hookworm, trichuriasis, ascariasis, trachoma, LF and onchocerciasis. These NTDs exhibit
considerable geographical overlap [1], at least if viewed at the country level [6]. It is thus
thought that a single structure, such as CDTI, CHDs or the National Malaria Control
Programme, could be readily used to deliver more than one treatment. Because the structures
are already in place, this would, in theory, only slightly increase costs if a component is
added or reduce costs if two structures are merged, while considerably expanding coverage
[4,6,51,52]. In Uganda, however, there is a limited geographical overlap between the
different NTDs (Figure 1), necessitating a more geographically targeted approach.
Furthermore, the structural changes required to deliver an integrated package are still being
undertaken. In the interim, it is already planned that the LF programme will provide
ivermectin in April each year and the onchocerciasis control programme will provide
ivermectin in October each year. In areas coendemic for LF and onchocerciasis, such an
approach has the potential to eliminate both diseases [53,54].
In addition to differences in delivery structure and target geographical areas, the frequency
of drug administration varies between control programmes. Treatment for STHs is
recommended every 6–12 months, whereas treatment for onchocerciasis and LF is
recommended annually. The actual frequency and number of rounds of ivermectin treatment
required to interrupt transmission of LF or onchocerciasis are unknown [29]. Although
schistosomiasis treatment using praziquantel is currently provided annually, longer
treatment intervals might become justified as infection levels decrease. Coordinating these
different treatment intervals represents a challenge for integration.
Treatment regimens for HAT and VL are too toxic and lengthy to be delivered outside a
health facility [23,42,55] and are thus unsuitable for inclusion in this new integrated
approach. A threat exists, therefore, that control of HAT, VL and other NTDs will continue
to be neglected, as attention is focused on diseases that have a population-based
chemotherapy strategy. Recent NTD advocacy has contributed to the allocation of funds for
the development of a new generation of control tools (drugs, diagnostics and vaccines) for
VL and HAT, in addition to other NTDs [e.g. the Drugs for Neglected Diseases initiative
(http://www.dndi.org) and Sabin Vaccine Institute (http://www.sabin.org)], but has had little
impact on the allocation of funds to deliver existing HAT and VL control tools. Until new
tools become available, control with existing, although imperfect, tools must be intensified
[42,56].
In addition to integrating treatment, there is considerable potential for integrated vector
control for several NTDs, which receives little mention. In Uganda, the same mosquito
species transmit both LF and malaria in the same districts [26]. Increasing the coverage with
long-lasting ITNs (LLINs), as part of the malaria control efforts, is thus likely to impact on
LF vector densities and transmission [57,58] and merits further investigation [Roles of
vector control and xenomonitoring in LF elimination
(http://whqlibdoc.who.int/hq/2002/WHO_CDS_CPE_PVC_2002.3.pdf)]. Use of LLINs is
also likely to provide personal protection against sandfly vectors of VL [59]. Because VL
and malaria are coendemic in Uganda, scaling up of LLIN coverage in the VL endemic area
would be a good investment in health.
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Challenges for integrated control
Approaches for integrated control are still being developed and best practice will only
emerge after experience of actual implementation. Opportunities for implementation on a
national scale are now being created through the USAID funding. In designing and
implementing country programmes, several operational challenges exist and integrated
control might not be as straightforward and cost-effective as it is portrayed [Strengthening
the potential of health systems in rural Africa
(http://bmj.bmjjournals.com/cgi/eletters/328/7448/1129)] [60]. Potential shortcomings
include an increased bureaucratic burden, leading to reduced effectiveness of health services
[Health services are badly needed to control malaria (and other diseases)
(http://bmj.bmjjournals.com/cgi/eletters/328/7448/1129)] [7]. Also, as the number of
interventions increases, the activities of the CDDs resemble those of a full-time job and the
CDDs cannot attend to other activities that generate income. The increased workload might
prove detrimental to their performance in any one activity, as already documented for the
onchocerciasis control programme [61], and lead to demands for incentives in compensation
for the work [62]. Whether, and to what extent, the capacity of CDDs in Uganda is
underused requires further investigation, but it is already apparent that all programmes that
heavily draw on them experience increasing demands for incentives [63,64]. These demands
could, potentially, be overcome by increasing the number of CDDs so that the workload of
each individual is reduced. However, to increase the pool of CDDs, more funding would be
needed for training, health education, monitoring and supervision.
The current model of integrated MDA differs from the more common understanding of
integration as ‘a process where disease control activities are functionally merged or tightly
coordinated with multifunctional health care delivery’ [7]. Therefore, another challenge is
the possibility that linking vertical control programmes might promote the development of a
parallel health-delivery system, with separate funding, drugs, delivery channels and staff
[The challenge of global health
(http://www.foreignaffairs.org/20070101faessay86103/laurie-garrett/the-challenge-of-
global-health.html)]. Ideally, drugs should be distributed from the centre to health facilities,
which then distribute the drugs to CDDs and schools, as part of their outreach activities.
Health workers should also be involved in training, monitoring and supervision. If the
programme is to be sustainable in the long term and not reliant on continual donor support, it
is essential that interventions are delivered through existing MoH staff and funded at
national and local levels.
Further challenges are the harmonization of information, education and communication
(IEC) messages and their effective delivery. To date, social mobilization and sensitization of
target communities have often been inadequate, because resources for activities, such as
surveys of knowledge, attitude and practice, development of IEC materials and community
meetings, were limited. Furthermore, for both the STH and schistosomiasis programme and
the onchocerciasis control programme, communities were sometimes not involved in the
selection of their CDDs. In these cases, communities were reluctant to participate in control
activities and CDDs were more likely to ‘drop out’ [63]. These experiences show that
resources are urgently needed to improve on development, implementation and evaluation of
the health-education component of each programme and communities must be empowered
to select their own health workers. An integrated approach will face the same challenges.
The safety and efficacy of certain drug combinations is also unknown [65]. Combinations
currently approved by the WHO [Preventive chemotherapy in human helminthiasis
(http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf)] are shown in Table 3.
Studies of coadministration of both ivermectin, albendazole and praziquantel and
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anthelmintic treatments and zithromax are required [60]. Implementation of integrated
chemotherapy that has unknown potential side effects must be accompanied by vigorous
pharmacovigilance. A general pharmacovigilance system is currently being put in place in
Uganda, but its implementation already poses numerous practical challenges [66]. These,
and the need for additional training, monitoring and supervision of health workers, should
limit implementation of an integrated package to a pilot area and be supported by a strong
operational research component designed to yield the necessary evidence on safety,
effectiveness and operational constraints [60].
Finally, monitoring and evaluation activities must be carefully designed and implemented, to
answer important operational questions and modify and support control packages, as
necessary. Guidance on the epidemiological aspects of evaluating helminth control
programmes is already available [67] and a WHO manual on evaluating integrated control is
currently being developed. However, evaluation of the health benefits of an integrated
control package represents a major challenge.
Concluding remarks
The success of integrated control depends on a clear understanding of the distribution and
epidemiology of the diseases to be targeted. In most countries, this information is
incomplete, requiring detailed surveys to establish areas of coendemicity and formulate
MDA packages accordingly. With the move towards integrated control, there is a need to
broaden the scope of research, including studies of the effectiveness and cost-effectiveness
of integrated control of NTDs compared with existing control programmes. There is also a
need to evaluate the impact of integration on existing health systems, including the quality
of health care and staffing levels. Efforts to implement integrated control must be
accompanied by investment in, and strengthening of, healthcare systems and human
resources, because these are prerequisites for the success of global health initiatives [68].
It is hoped that other health-sector donors will soon follow the example of the USAID and
start to support the unmet needs for control of NTDs. Resources are urgently required to
establish an evidence base for integrated control and curb the burden of diseases that cannot
be controlled through MDA. Case management of these diseases must become a functioning
component of the existing healthcare system [56]. Obvious gaps in the Ugandan context are
HAT and VL, which will not benefit from integrated control as it is currently planned.
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Figure 1.
Areas of Uganda endemic or coendemic for NTDs that are controlled using MDA of
preventative chemotherapy. Areas shown in red are endemic for schistosomiasis, light green
areas are endemic for onchocerciasis, yellow areas are endemic for VL and light blue areas
are endemic for LF. Dark blue areas indicate counties (administrative areas below district
level) coendemic for schistosomiasis and onchocerciasis, orange areas are districts in which
schistosomiasis and LF are coendemic and dark green areas are districts in which
schistosomiasis, LF and onchocerciasis are present. STHs are endemic throughout Uganda.
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Table 2
NTDs in Uganda
Disease Distributiona Nationwide burden Refs
A. lumbricoides and
T. trichiura
Unevenly distributed; the highest prevalence is in
southwest Uganda
Average prevalence of <10%, but >50% in
southwest Uganda
[14]
Hookworm Throughout Uganda (the prevalence is lower in the
northeast)
Prevalence of >50% [14]
Schistosomiasis In 30 districts, particularly near the shores of lakes
Albert and Victoria and along the Albert Nile
About 4 million cases; 16.7 million are at risk [15]
LF North of the Victoria Nile and in west Uganda Prevalence of circulating filarial antigens in
schoolchildren is 0.4–30.7%; 13.9 million are at
risk
[16]
Onchocerciasis In 27 districts; highly endemic in the west Nile region,
central shores of lake Albert, Mount Elgon and foci in
southwest Uganda
Greater than 2 million at risk; 1.36 million
infected
[17]
Dracunculiasis Eliminated as a public health problem Eliminated [18]
VL Pokot county and the Nakapiripirit district (northeast
Uganda)
Unknown; >600 cases treated per year, of which
70% are from Kenya
[10]
HAT Northwest Uganda, predominantly in the Adjumani,
Moyo, Arua and Yumbe districts
In 2005, 267 cases were reported
Southeast and east Uganda In 2005, 479 cases were reported [11,24]
Trachoma In 15 districts (according to HMIS records); a
nationwide survey is planned
Unknown [12]
Buruli ulcer Unknown Unknown
Leprosy Eliminated as a public health problem In 2004, 2.5 new cases per 100 000 population b
a
The number of districts quoted here and elsewhere in the document refers to the number prior to recent administrative changes that have divided
some of the previous districts.
b
GLRA/NTPL. Leprosy Status Report 2004. German Leprosy Relief Association/National TB and Leprosy Programme. Wandegeya, Kampala,
Uganda, 2004.
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Table 3
Summary of approved preventative schedules for helminthic diseases
Disease Treatment
LF Treat the entire population at risk using ALB and DEC or ALB and IVN
LF and onchocerciasis Treat the entire population at risk using ALB and IVN
LF and schistosomiasis Round 1: treat the entire population at risk using ALB and DEC or ALB and IVN
Round 2 (at least 1 week after Round 1): treat school-age children and adults at risk using PZQ
LF and STHs Round 1: treat the entire population at risk using ALB and DEC or ALB and IVN
Round 2 (after 6 months): if the prevalence of STH is ≥50%, treat school-age children using ALB or
MEB
LF, onchocerciasis and schistosomiasis Round 1: treat the entire population at risk using ALB and IVN
Round 2 (at least 1 week after Round 1): treat school-age children and adults at risk using PZQ
LF, onchocerciasis and STHs Round 1: treat the entire population at risk using ALB and IVN
Round 2 (after 6 months): if the prevalence of STH is ≥50%, treat school-age children using ALB or
MEB
Onchocerciasis Treat the entire population at risk in meso- and hyperendemic communities using IVN
Onchocerciasis and schistosomiasis Round 1: treat the entire population at risk in meso- and hyperendemic communities using IVN
Round 2 (at least 1 week after Round 1): treat school-age children and adults at risk using PZQ
Onchocerciasis and STHs Round 1: ALB (treat school-age children) and IVN (treat the entire population at risk in meso- and
hyperendemic communities)
Round 2 (after 6 months): if the prevalence of STH is ≥50%, treat school-age children using ALB or
MEB
Schistosomiasis Treat school-age children and adults at risk using PZQ
Schistosomiasis and STHs Round 1: ALB or MEB (treat school-age children) and PZQ (treat school-age children and adults
considered at risk)
Round 2 (after 6 months): if the prevalence of STH is ≥50%, treat school-age children using ALB or
MEB
STHs Round 1: treat school-age children using ALB or MEB
Round 2 (after 6 months): if the prevalence of STH is ≥50%, treat school-age children using ALB or
MEB
ALB, albendazole; DEC, diethylcarbamazine; IVN, ivermectin; MEB, mebendazole; PZQ, praziquantel; LF, lymphatic filariasis; STH, soil-
transmitted helminths.
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